Next-generation Proteomics-Based Discovery, Verification, and Validation of Urine Biomarkers for Bladder Cancer Diagnosis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We aimed to identify, verify, and validate a multiplex urinary biomarker-based prediction model for diagnosis and surveillance of urothelial carcinoma of bladder, using high-throughput proteomics methods. Materials and methods: Label-free quantification of data-dependent and data-independent acquisition of 12 and 24 individuals was performed in each of the discovery and verification phases using mass spectrometry, simultaneously using urinary exosome and proteins. Based on five scoring system based on proteomics data and statistical methods, we selected eight proteins. Enzyme-linked immunosorbent assay on urine from 120 patients with bladder mass lesions used for validation. Using multivariable logistic regression, we selected final candidate models for predicting bladder cancer. Results: Comparing the discovery and verification cohorts, 38% (50/132 exosomal differentially expressed proteins [DEPs]) and 44% (109/248 urinary DEPs) are consistent at statistically significance, respectively. The 20 out of 50 exosome proteins and 27 out of 109 urinary proteins were upregulated in cancer patients. From eight selected proteins, we developed two diagnostic models for bladder cancer. The area under the receiver operating characteristic curve (AUROC) of two models were 0.845 and 0.842, which outperformed AUROC of urine cytology. Conclusion: The results showed that the two diagnostic models developed here were more accurate than urine cytology. We successfully developed and validated a multiplex urinary protein-based prediction, which will have wide applications for the rapid diagnosis of urothelial carcinoma of the bladder. External validation for this biomarker panel in large population is required.
Abstract
Purpose: We aimed to identify, verify, and validate a multiplex urinary biomarker-based prediction model for diagnosis and surveillance of urothelial carcinoma of bladder, using high-throughput proteomics methods. Materials and methods: Label-free quantification of data-dependent and data-independent acquisition of 12 and 24 individuals was performed in each of the discovery and verification phases using mass spectrometry, simultaneously using urinary exosome and proteins. Based on five scoring system based on proteomics data and statistical methods, we selected eight proteins. Enzyme-linked immunosorbent assay on urine from 120 patients with bladder mass lesions used for validation. Using multivariable logistic regression, we selected final candidate models for predicting bladder cancer. Results: Comparing the discovery and verification cohorts, 38% (50/132 exosomal differentially expressed proteins [DEPs]) and 44% (109/248 urinary DEPs) are consistent at statistically significance, respectively. The 20 out of 50 exosome proteins and 27 out of 109 urinary proteins were upregulated in cancer patients. From eight selected proteins, we developed two diagnostic models for bladder cancer. The area under the receiver operating characteristic curve (AUROC) of two models were 0.845 and 0.842, which outperformed AUROC of urine cytology. Conclusion: The results showed that the two diagnostic models developed here were more accurate than urine cytology. We successfully developed and validated a multiplex urinary protein-based prediction, which will have wide applications for the rapid diagnosis of urothelial carcinoma of the bladder. External validation for this biomarker panel in large population is required.
참고문헌 (29)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- Kamat AM, "Bladder cancer", Lancet, 388, pp.2796~2810 (2016)
- Babjuk M, "European Association of Urology guidelines on non-muscle-invasive Bladder Cancer(TaT1 and carcinoma In situ) : 2019 update", Eur Urol, 76, pp.639~657 (2019)
- Chang SS, "Diagnosis and treatment of non-muscle invasive bladder cancer : AUA", SUO guideline, 2016, pp.196, 1021~1029
- Soria F, "Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over", Urologia, 80(Spec No 1), pp.1~ (2013)
- Chou R, "Urinary biomarkers for diagnosis of bladder cancer : a systematic review and meta-analysis", Ann Intern Med, 163, pp.922~931 (2015)
- Altelaar AF, "Next-generation proteomics : towards an integrative view of proteome dynamics", Nat Rev Genet, 14, pp.35~48 (2013)
- Liu YR, "Extracellular vesicles in bladder cancer : biomarkers and beyond", Int J Mol Sci, 19, pp.2822~ (2018)
- 정창욱, "Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform", Investigative and Clinical Urology, 60(4), pp.235~243 (2019), 대한비뇨의학회[DOI]
- Han D, "Proteomic analysis of mouse astrocytes and their secretome by a combination of FASP and StageTip-based, high pH, reversed-phase fractionation", Proteomics, 14, pp.1604~1609 (2014)
- Bruderer R, "Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen-treated three-dimensional liver microtissues", Mol Cell Proteomics, 14, pp.1400~1410 (2015)
- Tyanova S, "The MaxQuant computational platform for mass spectrometry-based shotgun proteomics", Nat Protoc, 11, pp.2301~2319 (2016)
- Cox J, "Andromeda : a peptide search engine integrated into the MaxQuant environment", J Proteome Res, 10, pp.1794~1805 (2011)
- Schwanhausser B, "Global quantification of mammalian gene expression control", Nature, 473, pp.337~342 (2011)
- Reiter L, "mProphet : automated data processing and statistical validation for large-scale SRM experiments", Nat Methods, 8, pp.430~435 (2011)
- George D, "SPSS for Windows step by step: a simple guide and reference. 11.0 update" (2003), Pearson Education
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves : a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Virtanen P, "SciPy 1.0: fundamental algorithms for scientific computing in Python", Nat Methods, 17, pp.261~272 (2020)
- Abbatiello SE, "Design, implementation and multisite evaluation of a system suitability protocol for the quantitative assessment of instrument performance in liquid chromatography-multiple reaction monitoring-MS(LC-MRM-MS)", Mol Cell Proteomics, 12, pp.2623~2639 (2013)
- D’Costa JJ, "A systematic review of the diagnostic and prognostic value of urinary protein biomarkers in urothelial bladder cancer", Bladder Cancer, 2, pp.301~317 (2016)
- Soukup V, "Panel of urinary diagnostic markers for non-invasive detection of primary and recurrent urothelial urinary bladder carcinoma", Urol Int, 95, pp.56~64 (2015)
- Santoni G, "Urinary markers in bladder cancer : an update", Front Oncol, 8, pp.362~ (2018)
- Frantzi M, "Developing proteomic biomarkers for bladder cancer : towards clinical application", Nat Rev Urol, 12, pp.317~330 (2015)
- Linden M, "Tumour expression of bladder cancer-associated urinary proteins", BJU Int, 112, pp.407~415 (2013)
- Li H, "Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma", Proteome Sci, 9, pp.21~ (2011)
- Zhang Z, "Depletion of CDC5L inhibits bladder cancer tumorigenesis", J Cancer, 11, pp.353~363 (2020)
- Rose M, "Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours", Carcinogenesis, 35, pp.727~736 (2014)
- Chen YT, "Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers", J Proteomics, 75, pp.3529~3545 (2012)
- Gao X, "Identification of key candidate genes and biological pathways in bladder cancer", PeerJ, 6, pp.e6036~ (2018)